Viela Bio, an AstraZeneca (MedImmune) spin-out launched last year with up to $250 million series A financing led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital. They just recently secured another $70+ million. The team centers its’ attention on severe autoimmune diseases by targeting critical pathways that represent the disease root cause. Bing Yao, Ph.D is Viela’s CEO. Viela’s pipeline includes 5 programs including one ready for Phase II.